CEACAM5 and neoplasm: A phase I/II clinical trial was started in 1996 to evaluate toxicity, pharmacokinetics, dosimetry, and anti-tumor activity of pRAIT using murine anti-CEA × anti-DTPA BsMAb F6x734 and a bivalent indium-DTPA hapten labeled with iodine-131, in 26 patients with metastatic MTC (Kraeber-Bodéré et al., 1999a).